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The widespread use of primaquine (PQ) and chloroquine (CQ), together, may be responsible for the relatively few, isolated cases
of chloroquine-resistant P. vivax (CQRPV) that have been reported from South America. We report here a case of P. vivax from
the Amazon Basin of Peru that recurred against normally therapeutic blood levels of CQ. Four out of 540 patients treated with
combination CQ and PQ had a symptomatic recurrence of P. vivax parasitemia within 35 days of treatment initiation, possibly
indicating CQ failure. Whole blood total CQ level for one of these four subjects was 95ng/ml on the day of recurrence. Based on
published criteria that delineate CQRPV as a P. vivax parasitemia, either recrudescence or relapse, that appears against CQ blood
levels >100ng/mL, we document the occurrence of a P. vivax strain in Peru that had unusually high tolerance to the synergistic
combination therapy of CQ + PQ that normally works quite well.
1.Introduction
P. vivax is the most prevalent cause of human malaria in
the Americas, accounting for more than 70% of total cases
reported [1]. Chloroquine (CQ) at a dose of 25mg/kg over
three days remains the ﬁrst line therapy for vivax malaria.
To prevent relapse, CQ is normally given in combination
with primaquine (PQ). PQ is given to all nonpregnant
patients greater than 6 months of age with normal activity
of glucose-6-phosphate dehydrogenase (G-6-PD). The Peru-
vian National Malaria Control Program changed from the
standard 14-day course of PQ at 0.25mg/kg/day to a 7-day
regimen of 0.5mg/kg/day in 1998. Both regimens achieve
a total adult PQ dose of 210mg which is assumed to be
widely eﬀective against the hypnozoite stage of P. vivax
strains acquired outside of Southeast Asia and the Indo-
Paciﬁc Islands. Widespread chloroquine resistance (CQR)
has been reported in some areas of the world, although, up
until now, only two conﬁrmed cases have been reported in
Peru [2, 3].
Recurrence of P. vivax following treatment can be classi-
ﬁed as recrudescence, which is the recurrence of parasitemia
originating from subpatent trophozoites that survived in the
blood following treatment, relapse which is the recurrence of
parasitemia originating from latent hypnozoites in the liver,
or reinfection with a new strain [2]. Recrudescence occurs
when the blood stage antimalarial drug such as chloroquine
fails, either due to inadequate dosing or resistance of the
blood stage parasites to the drug. Relapse can occur in the
absence of a speciﬁc treatment against the hypnozoite stage
or when the liver stage antimalarial drug such as primaquine
fails to completely eradicate the parasite from the liver. In
general, reappearance of parasitemia between 17 and 35








Figure 1: Map of Iquitos, Peru.
early relapse, or reinfection, whereas reappearance after 35
days is attributed to a relapse or reinfection [2]. Based
on the treatment sensitivity demonstrated by P. vivax to
blood levels of total CQ (parent compound CQ plus the
active desethylchloroquine metabolite, DCQ), a minimally
eﬀective concentration (MEC) of 100ng/mL was determined
as the criteria for separating between CQ-sensitive and
CQ-resistant strains of P. vivax, whether they arise from
recrudescence, relapse, or reinfection [2].
2.MaterialsandMethods
2.1. Study Sites. The present protocol studied the eﬃcacy of
three diﬀerent regimens of primaquine for the prevention of
relapses of P. vivax at three diﬀerent sites: Padre Cocha (PC),
S a nJ u a n( S J ) ,a n dS a n t aC l a r a( S C ) ,l o c a t e di no ra r o u n dt h e
city of Iquitos in the Department of Loreto in the Amazon
Basin of Peru (Figure 1).
2.2. Study Design. Between 2005 and 2008, a total of 540
informed and consenting subjects between 1 to 77 years
of age, with symptomatic microscopy-conﬁrmed P. vivax
monoinfection, were enrolled. Institutional review boards in
Peru and the United States had reviewed and approved the
study plan and procedures prior to any enrollment (796-
2004-J-OPD/INS and NMRC.2005.0005). Study participants
were divided into three arms, all of whom received the same
standard treatment dose of chloroquine (25mg base/kg body
weight divided into single daily doses over 3 days) but were
randomized to receive one of three regimens of PQ: (1)
0.5mg/kg daily for 5 days, (2) 0.5mg/kg daily for 7 days, or
(3) 0.25mg/kg daily for 14 days. Both CQ and PQ regimens
were started on the same day, and consumption of each
dose was directly observed. As part of the study protocol,
blood smears were collected and evaluated on days 1, 2,
3, 7, 14, 21, and 28, later every 2 weeks until 6 months,
and on each occasion when an enrolled study participant
returned to the clinic with malaria-like symptoms. Patients
who developed a recurrence of parasitemia during the 6-
month follow-up period were treated as recommended by
the Peruvian Ministry of Health (CQ: 25mg/kg base over 3
days: 10mg/kg on days 1 and 2, and 5mg/kg on day 3, plus
PQ: 0.5mg/kg daily for 7 days).
2.3. Laboratory. A blood smear was performed on day 0
and follow-up days. In the case of recurrence of parasitemia
within 17–35 days of starting treatment, 2mL of EDTA
blood were collected for determination of CQ blood levels
and P. vivax genotyping. Blood smears were stained with
Giemsa and independently read by two microscopists. The
ﬁnal parasite density was the average of the two densities. A
third slide was read in the case of discrepancy between the
ﬁrst two reads.
2.4. Chloroquine Levels. Three aliquots of 100µL of whole
blood from day-of-recurrence (D-R) samples were spotted
onto ﬁlter paper for later analysis by high performance
liquid chromatography (HPLC) to determine the levels of
CQ and its major metabolite, desethylchloroquine (DCQ) as
previously described [3].
2.5. Molecular Analysis. DNA was isolated from 200µLo f
whole blood-EDTA samples from D-0 and D-R by using a
QIAamp DNA Blood Mini Kit (QIAGEN, NL), following the
manufacturer’s instructions. All initial (D-0) and recurrent
(D-R) parasitemias were conﬁrmed as P. vivax monoinfec-
tions by PCR [4]. Genomic DNA of P. vivax was ampliﬁed
at the Pvmdr1 and Pvcrt loci and sequenced using BigDye
Terminator sequencing kit (Applied Biosystems, USA) on an
ABI 3130 automated DNA sequencer (Applied Biosystems,
USA) [5, 6].
3. Results
From the total of 540 patients enrolled in the study at the
three sites, four subjects had a recurrence of parasitemia
within the 35-day follow-up period. The study ﬁndings
evaluating the three primaquine treatment groups will be
published elsewhere. The four patients had fever or history
of fever, were between 4 and 11 years old, and had a
geometricmean(GM)parasitedensityof13,536parasites/µL
on D-0. The characteristics of these subjects are shown in
Table 1. Parasitemias recurred with symptoms on day 28 (2
patients), day 30, and day 32. However, the re-reading of
the routine, scheduled slides showed that the recurrence of
P. vivax parasitemia actually occurred earlier, but without
symptoms, on day 28 for SC105 (Table 1). Initial reading
of the day-32 slide for SC105 showed a mixed infection of
P. falciparum and P. vivax, but upon review of this slide
and reading of the duplicate and triplicate slides for this
patient, a monoinfection with P. vivax was determined. P.
vivax monoinfection, that is, the absence of P. falciparum,
was conﬁrmed in the day-32 whole blood sample of SC105
by PCR. This patient was treated with meﬂoquine andMalaria Research and Treatment 3
Table 1: Characteristics of recurrent vivax malaria cases and parasitemia levels throughout the follow-up period.
Patient no. Age/Sex PQ Arm
Parasitemia (asexual parasites/µL) by day of follow-up
Day 0 Day 2 Day 3 Day 7 Day 14 Day 21 Day 28 Day 30 Day-32
P C 0 4 6 9 / F 7 5 , 7 1 3 2 4 0000 4 6 6 — —
S J 0 0 41 1 / F 7 1 3 , 0 9 9 2 4 0000 1 2 — —
S C 0 5 8 7 / M 5 1 3 , 0 6 4 000000 1 , 5 2 2 —
S C 1 0 54 / F 1 4 3 4 , 3 4 0 3 6 0000 4 7 II — 2,495
IIParasitemia detected only in the second reading of the slides. This sample was not included in the analysis of CQ blood concentration or in genotyping.
Table 2: Responses to CQ/PQ treatment, CQ blood levels and genotyping analysis from patients with recurrence of parasitemia.
Patient no. Parasitologic response∗ Therapeutic response† CQ levels in blood (ng/mL) D-0 versus D-R
genotype
CQ DCQ Total CQ
PC046 RI (late) LPF 21 43 64 Diﬀerent
SJ004 RI (late) LPF BD∗∗ 23 23 Diﬀerent
SC058 RI (late) LPF 36 BD∗∗ 36 Same
SC105 RI (late) LCF 42 53 95 Same
∗RI (late), parasitological response, World Health Organization resistance levels, (Bruce-Chwatt, 1986).
†Only as reference: this classiﬁcation is no longer used for P. vivax; World Health Organization; Peter Bloland; 2003.
∗∗BD: below the limit of detection (<10 ng/mL).
artesunate for the presumed P. falciparum infection that only
later was determined to be a recurrent P. vivax infection.
In three patients, the levels of CQ plus DCQ were
subtherapeutic (<100ng/mL) on the day of recurrence
(Table 2). Only one patient, SC105, had a combined CQ
+D C Ql e v e lo f9 5 n g / m Li nw h o l eb l o o do nd a y3 2( t h e
initially recognized day of recurrence). Because parasitemia
was not detected initially on day 28, no venous blood sample
was collected from this subject on day 28, and the CQ level
could not be determined on the true day of recurrence.
Genotyping of Pvmdr1 and Pvcrt was performed on D-
0 and D-R blood samples from all four patients, because of
their possible association with chloroquine resistance in P.
vivax and as a means to determine whether the recurrence
was caused by the same or a diﬀerent strain of P. vivax.T w o
patients had diﬀerent Pvmdr1 genotypes in the D-0 and D-
R isolates, indicating either a reinfection or the appearance
of a second strain not detected in the D-0 sample (Tables 2
and 3). The remaining two, including SC105, had the same
Pvmdr1 genotype on D-0 and D-R, strongly suggesting that
their recurrent parasitemia was either a recrudescence or an
early relapse (Table 3). In the case of Pvcrt,a l l8s a m p l e sw e r e
identical with only one synonymous mutation compared to
the sequenced reference strain, P565 (CCT>CCC). None of
the mutations in either gene were reported to be associated
with CQ resistance in P. vivax.
4. Discussion
According to published criteria for classifying a P. vivax
treatment failure as CQ resistance [2], one of four patients
in our study would be considered a probable case of CQRPV.
Multiple criteria that underlie this determination are the
following: (1) GMP quality CQ, (2) proper weight-adjusted
dose determination, (3) complete and directly observed
consumption of all doses, (4) normal enteric absorption of
the drug, and (5) a CQ + DCQ blood level at the time of
recrudescence ≥100ng/mL.Inthisstudy,onepatient,SC105,
had a total CQ level of 95ng/mL in whole blood on day
32 (initially deﬁned as the day of recurrence). However, a
second reading of the slides later showed that there was
actually reappearance of parasitemia four days earlier on day
28. A third reading conﬁrmed the ﬁndings of the second
reading. Although a blood sample was not collected on day
28 for this patient, it is likely that the total chloroquine
concentration would have been higher on day 28 than on
the day it was actually measured, day 32. It seems likely,
although it cannot be said with complete certainty, that
this patient indeed was infected with a chloroquine-resistant
strain of P. vivax. We cannot say with certainty whether
the recurrent parasitemia was a late recrudescence or an
early relapse. Recrudescence is unlikely, given the fact that
CQ resistance in P. vivax in Peru is quite low [3], and
the combination of CQ + PQ is very eﬀective against CQ-
resistant malaria strains; PQ is reported to be even more
potent than verapamil in reversing CQ resistance [7, 8].
Early relapse due to failure of the PQ to eliminate the
hypnozoites seems more likely to have occurred, but if so,
this relapse occurred against an impressive block of PQ. The
recurrent parasites in the blood would have been exposed
to the otherwise eﬃcacious level of CQ remaining in the
blood on day 28, but now in the absence of PQ due to its
shorter half life, the remaining CQ was unable to eliminate
the recurrent CQ-resistant parasites. Upon the reappearance
of parasitemia, subject SC105 was treated with meﬂoquine
and artesunate for presumed falciparum malaria on day 32.4 Malaria Research and Treatment
Table 3: Pvmdr1 genotypes.
Patient number Pvmdr1
Day 0 D-R
PC046 V221/ T529(ACG)/ M908L/T958M/ L1022(CTA) V221/ T529(ACA)/ M908L/T958M/ L1022(TTA)
SJ004 V221L/ T529(ACA)/ M908L/T958M/ L1022(CTA) V221/ T529(ACG)/ M908L/T958M/ L1022(CTA)
SC058 V221/ T529(ACG)/ M908L/T958M/ L1022(CTA) V221/ T529(ACG)/ M908L/T958M/ L1022(CTA)
SC105 V221/ T529(ACG)/ M908L/T958/ L1022(CTA) V221/ T529(ACG)/ M908L/T958/ L1022(CTA)
Codons in bold have mutants genotypes.
After that, the patient was lost to followup, but it is
likely that the “accidental” treatment for falciparum malaria
successfully treated the recurrence of a CQ-resistant P. vivax
strain. The other three patients, PC46, SJ4, and SC58, were
successfully re-treated with CQ (25mg over 3 days) plus
PQ (0.5mg/kg daily for 7 days) according to the Peruvian
National Malaria Control Program policy with no further
reappearance of parasitemia.
It is understood that PQ total dose, more than schedule
or duration, is the determinant underlying eﬀective relapse
prevention [9, 10], and it is also recognized that the curative
action of PQ in eradicating the hypnozoite stage of P.
vivax is potentiated by concurrent CQ or quinine therapy
[11, 12]. Primaquine works synergistically with a variety of
drugs [13–16], and the combination of chloroquine plus
primaquine was demonstrated to overcome chloroquine
resistance in both P. yoelii [17]a n dP. vivax [18]. More
recently, primaquine is also shown to work synergistically
with chloroquine against chloroquine-resistant P. falciparum
[7, 8].
Acting on numerous cases of P. vivax recrudescence
and/or relapse by the standard 14-day PQ regimen of
15mg/day from locations throughout the Old and New
World, the US Centers for Disease Control (CDC) recently
revised its dosing recommendation for PQ antirelapse ther-
apyandradicalcure[12,19,20].Underthisnewadvisement,
the adult dose of PQ is increased from 15 to 30mg daily
for 14 days, and the pediatric dose has been comparably
increased from 0.25 to 0.5mg/kg/day [12]. Under the new
CDC recommendation, which has not yet been approved
by the US Food and Drug Administration (FDA), the four-
year-old Peruvian subject, SC105, would have received a
total pediatric PQ dose of 119mg, considered suﬃcient to
eliminate the PQ tolerant Chesson-type forms of P. vivax
found in Southeast Asia and the Western Paciﬁc [10, 21, 22].
The patient was in the 14-day arm of this study that received
0.25mg/kg daily of PQ for 14 days, which in this 17kg child
would be a total indicated dose of 59.5mg PQ. In actuality,
this subject received a half tablet (7.5mg) of PQ daily which
amounted to a 14-day total dose of 105mg. This total dose,
although slightly less than the new CDC recommendation,
was considerably higher than the total pediatric dose of
59.5mg achieved under the “old” CDC recommendation.
The patient was scheduled to receive 25mg/kg CQ base over
3days,whichperherweightof17kgshouldhavebeenatotal
dose of 425mg CQ base. In actuality, she received a 150mg
base tablet per day, for a total dose of 450mg CQ base. On
the day that her recurrent parasitemia was detected, the level
of total CQ in her blood was at least 95ng/mL and possibly
greater than 100ng/mL, the minimum therapeutic level [2].
The association between mutations in Pvmdr1 and Pvcrt
and CQ resistance in P. vivax is not the same as the strong
association between the orthologous genes in P. falciparum
andCQresistanceinthisorganism.Noobviousmutationsin
Pvmdr1andPvcrt tentativelylinkedtochloroquineresistance
were found in these samples. Codon 976 in Pvmdr1, studied
for its feasible association to CQR [5], was wild-type in all
eight D-0 and D-R samples. Although we used the Pvmdr1
and Pvcrt gene sequences to distinguish between whether
the recurrent strains were the same or diﬀerent from the
original strains, this analysis is limited due to the low level of
heterogeneity in their sequences in Peruvian strains. As such,
while any diﬀerence in sequences of D-0 and D-R represents
ac l e a rd i ﬀerence in the two strains, the same sequence
detected on D-0 and D-R may simply happen by chance and
may not indicate that the two strains are identical.
While this report conﬁrms previously reported low-level
CQ resistance by P. vivax in the Peruvian Amazon region,
it is signiﬁcant in reporting the ﬁrst occurrence in Peru of
a failure of the standard CQ + PQ combination therapy
to achieve radical cure. Importantly, this treatment failure
occurredinthecontextofaclinicaltrialinwhich(1)alldrugs
used were produced under USFDA regulations, (2) dose was
carefully determined according to the subject’s weight, (3)
PQ treatment was administered with food to reduce gastric
upset/improve drug absorption, and (4) consumption of
each treatment dose of drug was fullysupervised and directly
observed.
The recurrence of P. vivax following combined therapy
with chloroquine and high-dose primaquine is unexpected
in South America, where in vivo testing has demonstrated
relatively few valid cases of CQ resistance [3, 23]. Guyana
has been the only other nation in South America that has
reported failure of CQ-PQ combination therapy, but in
multiple adult cases, against both low (15mg/day) and high
(30mg/day) doses of PQ, and with parasitemias appearing
six weeks following treatment [23]. Health providers and
travelers should be aware that such diﬃcult cases occur even
when there is little evidence of resistance in the region. As in
the earlier study of Ruebush et al. [3], it is interesting that all
four current cases of CQ failure were in children, less than 16
years old. Three of the patients in the current study and one
of the patients in the previous study had suboptimal levels
of chloroquine in the blood on the day of failure. It may beMalaria Research and Treatment 5
that children fail to absorb the full dose of chloroquine or
else eliminate the drug from their systems more rapidly than
adults. We did not verify adequate CQ absorption in any of
thepatients.OnlyafewstudieshavelookedatCQabsorption
in children but never in conjunction with PQ. Future studies
should address the absorption of CQ and PQ in children as
compared to adults.
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